Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

Azacitidine monotherapy versus combination regimens as post-allogeneic transplantation maintenance in high-risk myeloid malignancies: A retrospective cohort Study

Ying Shen, Pengyu Zhang, Aili He, Jianli Wang, Jie Liu, Wanhong Zhao, Liufang Gu, Jin Wang, Bo Lei, Xueying Li, Yun Yang

Blood (2025) 146 (Supplement 1): 2499.

https://doi.org/10.1182/blood-2025-2499

Published: 2025

Journal Articles

Association of combined IKZF1plus genotype and ABL1 mutations with outcomes in adult BCR::ABL1-positive acute lymphoblastic leukemia

Cheng Wang, Jianfeng Li, Weiyang Liu, Yuchen Yan, Li-Jun Peng, Jiayi Ren, Yongmei Zhu, Xiangqin Weng, Jiong Hu, Yuanfang Liu, Jie Hao, Weiping Zhang, Duohui Jing, Jian-Qing Mi, JIN WANG

Blood (2025) 146 (Supplement 1): 6880.

https://doi.org/10.1182/blood-2025-6880

Published: 2025

Journal Articles

Therapeutic effect of menin inhibitors is reversible in AML treatment and could be enhanced by the targeting of differentiation associated chromatin complex

Zhong Fan, John Mosior, Yanan Jiang, Jin Wang, Chun-Wei Chen, Xiaotian Zhang

Blood (2025) 146 (Supplement 1): 3295.

https://doi.org/10.1182/blood-2025-3295

Published: 2025

Journal Articles

A real world study of inotuzumab ozogamicin for the treatment of B-cell acute lymphoblastic leukemia: Multi-center result from SH-ALL group

Yuchen Yan, Ligen Liu, Jie Hao, Xiaofeng Han, Ping Li, Libing Wang, Li Yang, Yong Tang, Cheng Wang, Weiyang Liu, Jiayi Ren, Jiong Hu, Jianmin Yang, Qi Zhu, Aibin Liang, Jian Hou, Xianmin Song, Jianqing Mi, JIN WANG

Blood (2025) 146 (Supplement 1): 6830.

https://doi.org/10.1182/blood-2025-6830

Published: 2025

Journal Articles

Simvastatin targets the cholesterol–bile acid axis to improve ALL survival by remodeling the metabolic microenvironment

Junyu Wang, Bo Jiao, Tuantuan Gui, Xuan Liu, Shan-Shan Guo, Cheng Wang, Weiyang Liu, Li-Jun Peng, Jiayi Ren, Ming Zhang, Yun Tan, Duohui Jing, Jian-Qing Mi, Tong Yin, Hai Fang, Sai-Juan Chen, JIN WANG

Blood (2025) 146 (Supplement 1): 3362.

https://doi.org/10.1182/blood-2025-3362

Published: 2025

Journal Articles

Long-term follow-up for newly diagnosed BCR::ABL1 negative B cell acute lymphoblastic leukemia from China: 10-year outcome of RJ-ALL 2014 protocol

Jiayi Ren, Li-Jun Peng, Weiyang Liu, Jiong Hu, Cheng Wang, Yuchen Yan, Yuanfang LIU, Weiping Zhang, JIN WANG, Jian-Qing Mi

Blood (2025) 146 (Supplement 1): 3333.

https://doi.org/10.1182/blood-2025-3333

Published: 2025

Journal Articles

Long-read profiling of structural variants reveals mechanisms of chemo-resistance and prognostic heterogeneity in acute lymphoblastic leukemia

Xiaofang Ma, Minghao Jiang, JIN WANG, Jian-Qing Mi, Jason W.H. Wong, Duohui Jing

Blood (2025) 146 (Supplement 1): 1585.

https://doi.org/10.1182/blood-2025-1585

Published: 2025

Journal Articles

Real-world efficacy of inaticabtagene autoleucel in adult B-cell acute lymphoblastic leukemia patients with high-risk molecular alterations

Blood (2025) 146 (Supplement 1): 6865.

https://doi.org/10.1182/blood-2025-6865

Published: 2025

Journal Articles

Efficacy and safety profile of inaticabtagene autoleucel in Chinese adult patients with B-cell acute lymphoblastic leukemia who relapsed after their transplant: Insights from real-world data

Fen Zhou, Yuhua Li, Ying Wang, Xi Zhang, Jianmin Yang, Xiaobing Huang, JIN WANG, Xianmin Song, Xinsheng Xie, Li Wang, Jie Jin, Liye Zhong, Aibin Liang, Zhenyang Gu, Shengli Xue, Er-Lie Jiang, Baohong Ping, Heng Mei

Blood (2025) 146 (Supplement 1): 6859.

https://doi.org/10.1182/blood-2025-6859

Published: 2025

Journal Articles

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with Philadelphia chromosome-positive b-ALL: Insights from real-world data

Blood (2025) 146 (Supplement 1): 6855.

https://doi.org/10.1182/blood-2025-6855

Published: 2025

Journal Articles

A-319, a CD3xCD19 T cell engager, monotherapy for patients with refractory/relapsed B-cell acute lymphoblastic leukemia (r/r B-ALL)

Blood (2025) 146 (Supplement 1): 6853.

https://doi.org/10.1182/blood-2025-6853

Published: 2025

Journal Articles

Real-world study on the impact of continuous treatment dose interruption or reduction of COVALENT BTK inhibitors on efficacy: A 7-year follow-up in chronic lymphocytic leukemia specialized clinics at tertiary hospitals in shanghai, China

Jiaojiao Zhang, Xiaozhong Shen, Jiong Hu, Lu Jiang, JIN WANG, Jian-Qing Mi

Blood (2025) 146 (Supplement 1): 5688.

https://doi.org/10.1182/blood-2025-5688

Published: 2025

Journal Articles

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with B-cell acute lymphoblastic leukemia: Insights from real-world data

Blood (2025) 146 (Supplement 1): 5122.

https://doi.org/10.1182/blood-2025-5122

Published: 2025

Journal Articles

Transcriptional remodeling shapes therapeutic vulnerability to necroptosis in acute lymphoblastic leukemia

Anna Saorin, Anna Dehler, Bartimée Galvan, Fabio Steffen, Marine Ray, Dong Lu, Xin Yu, James Kim, Aneta Drakul, Samanta Kisele, Jin Wang, Jean-Pierre Bourquin, Beat C. Bornhauser

Blood (2025) 146 (7): 861–873.

https://doi.org/10.1182/blood.2025028938

Published: 2025

Includes: Supplemental data

Journal Articles

CD44-mediated metabolic rewiring is a targetable dependency of IDH-mutant leukemia

Junhua Lyu, Yuxuan Liu, Ningning Liu, Hieu S. Vu, Feng Cai, Hui Cao, Pranita Kaphle, Zheng Wu, Giovanni A. Botten, Yuannyu Zhang, Jin Wang, Sarada Achyutuni, Xiaofei Gao, Ilaria Iacobucci, Charles G. Mullighan, Stephen S. Chung, Min Ni, Ralph J. DeBerardinis, Jian Xu

Blood (2025) 145 (14): 1553–1567.

https://doi.org/10.1182/blood.2024027207

Published: 2025

Includes: Supplemental data

Journal Articles

Low-Risk Group Identified By a Refined Prognostic System Integrating Both IKZF1 plus genotyping and MRD Assessment in Adult BCR::ABL1 -Positive Acute Lymphoblastic Leukemia

Cheng Wang, Jianfeng Li, Weiyang Liu, Han Yan, Yuchen Yan, Lingling Zhao, Jiayi Ren, Lijun Peng, Jiaojiao Zhang, Yuanfang Liu, Xiangqin Weng, Yongmei Zhu, Weiping Zhang, Jie Xu, Duohui Jing, Jian-Qing Mi, Jin Wang

Blood (2024) 144 (Supplement 1): 1457.

https://doi.org/10.1182/blood-2024-209664

Published: 2024

Journal Articles

Combination of Venetoclax and Daratumumab Plus CAG Regimen in Adult T-Cell Acute Lymphoblastic Leukemia with Persistent Positive Minimal Residual Disease

Lijun Peng, Yuting Dai, Jiayi Ren, Weiyang Liu, Jie Xu, Weiping Zhang, Jin Wang, Jian-Qing Mi

Blood (2024) 144 (Supplement 1): 4210.

https://doi.org/10.1182/blood-2024-204740

Published: 2024

Journal Articles

A Hiplot-Based Web Application for the Rapid Prediction of Adult BCR::ABL1 -Positive and BCR::ABL1 -like B-Cell Precursor Acute Lymphoblastic Leukemia

Jianfeng Li, Yuchen Yan, Cheng Wang, Weiyang Liu, Han Yan, Lingling Zhao, Xiangqin Weng, Yongmei Zhu, Jiayi Ren, Lijun Peng, Jiaojiao Zhang, Yuanfang Liu, Weiping Zhang, Jie Xu, Duohui Jing, Jian-Qing Mi, Jin Wang

Blood (2024) 144 (Supplement 1): 5926.

https://doi.org/10.1182/blood-2024-210369

Published: 2024

Journal Articles

Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial

Blood (2024) 144 (Supplement 1): 836.

https://doi.org/10.1182/blood-2024-208355

Published: 2024

Journal Articles

Abbv-453: A Highly Potent and Selective Next Generation Small Molecule Inhibitor of BCL-2

Darren C Phillips, Luzivette Robles-Cardona, Cory Alvey, Justin Ingram, Lloyd T Lam, Ziping Yang, Jacob J Riehm, Jun Chen, Matthew Kurnick, Peter Kovar, Jin Wang, George Doherty, Vikram Bhat, Yujia Dai, Andrew Judd, Andrew Souers

Blood (2024) 144 (Supplement 1): 4966.

https://doi.org/10.1182/blood-2024-205998

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Azacitidine monotherapy versus combination regimens as post-allogeneic transplantation maintenance in high-risk myeloid malignancies: A retrospective cohort Study

Association of combined IKZF1plus genotype and ABL1 mutations with outcomes in adult BCR::ABL1-positive acute lymphoblastic leukemia

Therapeutic effect of menin inhibitors is reversible in AML treatment and could be enhanced by the targeting of differentiation associated chromatin complex

A real world study of inotuzumab ozogamicin for the treatment of B-cell acute lymphoblastic leukemia: Multi-center result from SH-ALL group

Simvastatin targets the cholesterol–bile acid axis to improve ALL survival by remodeling the metabolic microenvironment

Long-term follow-up for newly diagnosed BCR::ABL1 negative B cell acute lymphoblastic leukemia from China: 10-year outcome of RJ-ALL 2014 protocol

Long-read profiling of structural variants reveals mechanisms of chemo-resistance and prognostic heterogeneity in acute lymphoblastic leukemia

Real-world efficacy of inaticabtagene autoleucel in adult B-cell acute lymphoblastic leukemia patients with high-risk molecular alterations

Efficacy and safety profile of inaticabtagene autoleucel in Chinese adult patients with B-cell acute lymphoblastic leukemia who relapsed after their transplant: Insights from real-world data

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with Philadelphia chromosome-positive b-ALL: Insights from real-world data

A-319, a CD3xCD19 T cell engager, monotherapy for patients with refractory/relapsed B-cell acute lymphoblastic leukemia (r/r B-ALL)

Real-world study on the impact of continuous treatment dose interruption or reduction of COVALENT BTK inhibitors on efficacy: A 7-year follow-up in chronic lymphocytic leukemia specialized clinics at tertiary hospitals in shanghai, China

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with B-cell acute lymphoblastic leukemia: Insights from real-world data

Transcriptional remodeling shapes therapeutic vulnerability to necroptosis in acute lymphoblastic leukemia

CD44-mediated metabolic rewiring is a targetable dependency of IDH-mutant leukemia

Low-Risk Group Identified By a Refined Prognostic System Integrating Both IKZF1 plus genotyping and MRD Assessment in Adult BCR::ABL1 -Positive Acute Lymphoblastic Leukemia

Combination of Venetoclax and Daratumumab Plus CAG Regimen in Adult T-Cell Acute Lymphoblastic Leukemia with Persistent Positive Minimal Residual Disease

A Hiplot-Based Web Application for the Rapid Prediction of Adult BCR::ABL1 -Positive and BCR::ABL1 -like B-Cell Precursor Acute Lymphoblastic Leukemia

Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial

Abbv-453: A Highly Potent and Selective Next Generation Small Molecule Inhibitor of BCL-2

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only